Currently out of the existing stock ratings of Nathan Weinstein, 38 are a BUY (92.68%), 3 are a HOLD (7.32%).

Nathan Weinstein

Work Performance Price Targets & Ratings Chart

Analyst Nathan Weinstein, currently employed at CITI, carries an average stock price target met ratio of 30.39% that have a potential upside of 16.33% achieved within 45 days.

Nathan Weinstein’s has documented 68 price targets and ratings displayed on 18 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on EVGN, Evogene at 12-Sep-2022.

Wall Street Analyst Nathan Weinstein

Analyst best performing recommendations are on AMRN (AMARIN PLC).
The best stock recommendation documented was for AMRN (AMARIN PLC) at 10/31/2019. The price target of $460 was fulfilled within 15 days with a profit of $131.6 (40.07%) receiving and performance score of 26.72.

Average potential price target upside

of $86.7 (25.04%) on AMRN (AMARIN PLC).
of $8.39 (54.52%) on ATAI (ATAI LIFE SCIENCES BV).
of $126.4 (33.83%) on DRIO (DARIOHEALTH CORP).

ATAI ATAI Life Sciences BV CDTX Cidara Therapeutics DRIO DarioHealth Corp ENVB Enveric Biosciences KTRA Kintara Therapeutics SCYX Scynexis VNRX Volitionrx Ltd IMUX Immunic MDWD Mediwound Ltd ORMP Oramed Pharmaceuticals CMMB Chemomab Therapeutics Ltd DRC ENTX Entera Bio Ltd IINN Inspira Technologies Oxy BHN Ltd ACST Acasti Pharma AVGR Avinger EVGN Evogene KIN Kindred Biosciences AMRN Amarin PLC

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score